Gerresheimer Shares Navigate Index Exit and Acquisition Speculation

German packaging firm Gerresheimer faces SDAX exit due to delayed 2025 audit, but takeover speculation at an 80% premium cushions the stock's fall. BaFin investigates accounting practices.

The German packaging specialist Gerresheimer finds itself at a complex crossroads, officially confirmed yesterday to be exiting the SDAX index. This development stems from the company's admission that its audited financial statements for 2025 will not be finalized by the March 31 deadline. While appearing procedural, this delay triggers significant consequences, forcing index funds to divest their holdings and putting the company in breach of certain credit agreements. Counterbalancing this pressure, persistent rumors of a potential takeover have provided notable support to the share price in recent sessions.

Takeover Premium Offsets Downward Momentum

Amidst the corporate turmoil, a report from Reuters indicated that U.S.-based packaging group Silgan Holdings is considering a takeover bid exceeding €40 per share. When measured against Friday's closing price of €20.94, this represents a potential premium of approximately 80%. This speculation is a key factor explaining why the equity has not experienced a more severe decline; the prospect of an acquisition is effectively cushioning the downward pressure from the index exclusion and financial uncertainties.

The shareholder base reflects a divided sentiment. On one side, the Deutsche Schutzvereinigung für Wertpapierbesitz (DSW) is examining potential claims for damages. Conversely, investment funds including the CastleKnight Master Fund and Deka Investment have reportedly established new positions at the depressed price level, signaling a view of potential value.

Audit Investigations Halt Financial Reporting

At the heart of the reporting delay is an extensive audit process. Beyond its regular auditor, KPMG, a second firm—Grant Thornton—has been examining the company's books for several months. This additional scrutiny was initiated by the German financial regulator, BaFin, which launched an investigation in September 2025 and expanded its scope in February. The focus of the probe is whether Gerresheimer improperly recognized revenue and costs related to so-called "bill-and-hold" agreements, a potential violation of IFRS accounting standards.

With these investigations ongoing, the company cannot issue certified financial statements. Gerresheimer now targets June 2026 for the completion of its 2025 audit.

The financial repercussions are substantial. The company anticipates non-cash impairment charges between €220 million and €240 million, primarily linked to technology projects at its Sensile Medical AG subsidiary and the planned closure of a facility in Chicago Heights. Furthermore, the dividend has been reduced to the statutory minimum of €0.04 per share.

Critical Dates and a Path Forward

Gerresheimer's share price currently trades roughly 40% below its 200-day moving average, a stark indicator of eroded market confidence. Over a twelve-month horizon, the stock shows a loss of nearly 75%.

Two upcoming events will be crucial for the company's trajectory. The first is the publication of the audited 2025 financial statements, now scheduled for June 2026. The second is the interim report due on July 14, 2026. These documents will provide the market with essential evidence to assess the robustness of the current year's revenue guidance, which stands at €2.3 to €2.4 billion, and will clarify the outcome of ongoing discussions with the company's lenders.